Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab plus R-CHOP in ctDNA high-risk untreated diffuse large B-cell lymphoma
2023-504994-19-00Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoint: End-of-treatment complete response rate. Started Jun 2020; status: completed.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-504994-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504994-19-00.